Unknown

Dataset Information

Choosing Non-Vitamin K Antagonist Oral Anticoagulants: Practical Considerations We Need to Know.


ABSTRACT:

Background

Warfarin is a well-established agent for use in the prevention of stroke or systemic embolic event (SEE) in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of venous thromboembolism (VTE). However, management of patients requiring oral anticoagulation with warfarin can be complicated by the need for frequent monitoring, drug-drug and drug-food interactions, and a variable response based on genetic polymorphisms. The non-vitamin K antagonist oral anticoagulants (NOACs) were developed as alternatives to warfarin; they do not require routine monitoring and have predictable pharmacokinetics, fewer drug-drug interactions, and limited drug-food interactions. Four NOACs-dabigatran, rivaroxaban, apixaban, and edoxaban-have received approval from the US

SUBMITTER: Amin A 

PROVIDER: S-EPMC5158161 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature